Abstract 397P
Background
Dexamethasone is the standard premedication for preventing nausea, vomiting and hypersensitivity reactions but the incidence of oxaliplatin hypersensitivity is varied. This study aimed to compare the incidence of any grade of oxaliplatin hypersensitivity between using the Y-site co-infusion of oxaliplatin and dexamethasone or standard premedication with intravenous dexamethasone to prevent hypersensitivity reactions (HSRs) and also to compare the degree of venous pain, objective response rate (ORR), progression free survival (PFS) and common adverse events.
Methods
Patients with stage III and IV of colorectal cancer who received capecitabine and oxaliplatin (CAPEOX) regimen at least 3 cycles from March 2022 to March 2023 were enrolled. At the 4th cycle, all enrolled patients were randomly assigned to receive either Y-site co-infusion of oxaliplatin and dexamethasone (arm A) or standard premedication with intravenous dexamethasone followed by Y-site co-infusion of oxaliplatin and placebo (arm B). The incidence of HSRs and the degree of venous pain between arm A and arm B were analyzed by using Chi-square and log-rank test was used for evaluate PFS.
Results
Nineteen of 37 patients were enrolled to arm A, and 18 of 37 patients were enrolled to arm B. There was no incidence of any grade of HSRs in both groups. The incidence of severe venous pain (grade 3) based on WHO classification between arm A and arm B were 16% and 39%, respectively (relative risk 0.41, 95% CI 0.12-1.33, P-value=0.114). The mean change of venous pain score between arm A and arm B based on numerical rating scale (NRS) were 5.01 and 5.64, respectively (P-value=0.402). There were no differences in ORR, PFS and common adverse events between two groups.
Conclusions
There was no incidence of any grade of HSRs between groups, so we could not conclude that using the Y-site co-infusion of oxaliplatin and dexamethasone was effective than standard premedication with intravenous dexamethasone for preventing HSRs from oxaliplatin administration. However, an incidence of severe venous pain may be reduced via through Y-site co-infusion of oxaliplatin and dexamethasone.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Institutional Review Board of Royal Thai Army Medical Department (IRBRTA R194h/64).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract